Thrombosis Journal is the official journal of the Asian-Pacific Society on Thrombosis and Hemostasis.
Members of APSTH are entitled to a 15% discount on the article processing charge.
Page 4 of 10
Thrombopoietin was posited to exist in 1958 and cloned in 1994, and in the ensuing two decades we have learned a great deal about the physiology and pathology of the primary regulator of thrombopoiesis. This p...
Citation: Thrombosis Journal 2016 14(Suppl 1):40
Thrombosis and coagulopathy are the commonest hematological manifestations of envenomation of Russell’s viper venom (RVV). Factor X is activated by a factor X-activating enzyme from Russell’s viper venom (RVV-...
Citation: Thrombosis Journal 2016 14(Suppl 1):38
As life expectancy greatly increases in persons with hemophilia (PWH), more age-related diseases such as cancer and cardiovascular disease (CVD) emerge among this patient group. The aim of this study was to re...
Citation: Thrombosis Journal 2016 14(Suppl 1):34
Retrospective and prospective studies unambiguously show that prophylactic treatment of severe hemophilia A or B should be started as primary prophylaxis at 1–2 years’ of age and ideally before the first joint...
Citation: Thrombosis Journal 2016 14(Suppl 1):30
Platelets are central mediators of thrombosis and hemostasis. At the site of vascular injury, platelet accumulation (i.e. adhesion and aggregation) constitutes the first wave of hemostasis. Blood coagulation, ...
Citation: Thrombosis Journal 2016 14(Suppl 1):29
Platelets play a key role in the pathophysiological processes of hemostasis and thrombus formation. However, platelet functions beyond thrombosis and hemostasis have been increasingly identified in recent year...
Citation: Thrombosis Journal 2016 14(Suppl 1):27
Thrombosis is a common complication in cancer patients. Although the major inherited risk factors for thrombophilia are different between Asians and Caucasians, the main acquired risk factors that are associat...
Citation: Thrombosis Journal 2016 14(Suppl 1):26
Venous thrombosis which mainly manifests as deep vein thrombosis of the leg or pulmonary embolism occurs in 1 per 1000 per year. It occurs due to interacting genetic, environmental and behavioral risk factors....
Citation: Thrombosis Journal 2016 14(Suppl 1):24
Venous thromboembolism (VTE), which constitutes pulmonary embolism and deep vein thrombosis, is a common disorder associated with significant morbidity and mortality. Landmark trials have shown that direct ora...
Citation: Thrombosis Journal 2016 14(Suppl 1):23
Hemophilia is the most well-known hereditary bleeding disorder, with an incidence of one in every 5000 to 30,000 males worldwide. The disease is treated by infusion of protein products on demand and as prophyl...
Citation: Thrombosis Journal 2016 14(Suppl 1):22
The antiphospholipid syndrome (APS) is an autoimmune disease characterised by a procoagulant state that predisposes to recurrent thrombosis and miscarriages. Two major discoveries have advanced our understandi...
Citation: Thrombosis Journal 2016 14(Suppl 1):20
Snake venoms affect blood coagulation and platelet function in a complex manner. However, two classes of venom proteins, snaclecs and disintegrins have been shown to specifically target receptors including GPI...
Citation: Thrombosis Journal 2016 14(Suppl 1):18
The group of new oral anticoagulants or NOACs, now termed direct oral anticoagulants or DOACs, with their favourable results from large scale phase III clinical trials, represent a major advancement and expand...
Citation: Thrombosis Journal 2016 14(Suppl 1):17
Disseminated intravascular coagulation (DIC) is a serious disease that, in the presence of underlying disease, causes persistent, generalized, marked coagulation activation. Early treatment based on an appropr...
Citation: Thrombosis Journal 2016 14:42
We tested the hypothesis that disseminated intravascular coagulation (DIC) during the early phase of post-cardiopulmonary resuscitation (CPR) is associated with systemic inflammatory response syndrome (SIRS), ...
Citation: Thrombosis Journal 2016 14:43
Aortic thrombosis is a rare disease and only a few cases of the disease, especially associated with chemotherapy for malignant diseases and/or blood diseases, have been previously reported. Although Virchow’s ...
Citation: Thrombosis Journal 2016 14:16
Factor Xa inhibitor is a key drug in the coagulation cascade. Parenteral anticoagulation using low molecular weight heparin or fondaparinux is the recommended form of treatment for most patients presenting wit...
Citation: Thrombosis Journal 2016 14:15
Vitamin K antagonists (VKAs) are effective oral anticoagulants that are titrated to a narrow therapeutic international normalized ratio (INR) range. We reviewed published literature assessing the impact of INR...
Citation: Thrombosis Journal 2016 14:14
Guidelines from the Japanese Circulation Society recommend prophylaxis with anticoagulation plus intermittent pneumatic compression or graduated compression stockings (GCS) among patients at the highest risk f...
Citation: Thrombosis Journal 2016 14:13
The need for anticoagulation therapy (AC) in patients with subsegmental pulmonary embolism (SSPE) diagnosed by computed tomography of the pulmonary arteries (CTPA) has been questioned, as these patients run lo...
Citation: Thrombosis Journal 2016 14:12
Citation: Thrombosis Journal 2016 14:11
Dabigatran etexilate may be underutilized in geriatric patients because of inadequate clinical experience in individuals with severe renal impairment and post-marketing reports of bleeding events. Assessing th...
Citation: Thrombosis Journal 2016 14:10
In hereditary spherocytosis with severe anemia, splenectomy is a recommended treatment. However, the spleen carries an important role both in immune function and coagulation. The increased risk of bacterial in...
Citation: Thrombosis Journal 2016 14:9
Thromboprophylaxis is recommended for patients undergoing total hip or total knee replacement (THR, TKR). An international, open-label, prospective, observational, single-arm study in a routine clinical settin...
Citation: Thrombosis Journal 2016 14:8
Studies show the In-hospital Mortality for Pulmonary embolism using Claims daTa (IMPACT) rule can accurately identify pulmonary embolism (PE) patients at low-risk of early mortality in a retrospective setting ...
Citation: Thrombosis Journal 2016 14:7
Several autoimmune skin disorders are characterised by an increased risk of thrombosis, with bollous pemphigoid carrying a higher risk than pemphigus vulgaris (PV). We describe the case of a middle aged gentle...
Citation: Thrombosis Journal 2016 14:6
The Editors of Thrombosis Journal would like to thank all of our reviewers who have contributed to the journal in Volume 13 (2015) and whose valuable support is fundamental to its success.
Citation: Thrombosis Journal 2016 14:5
Data estimating the annual incidence of venous thromboembolism (VTE) in France, taking into account both hospital and community settings, are very lacking.
Citation: Thrombosis Journal 2016 14:4
Cancer patients are at increased risk for venous thromboembolism (VTE).
Citation: Thrombosis Journal 2016 14:3
Despite the association of cancer-derived circulating tissue factor (TF)-containing microvesicles and hypercoagulable state, correlations with the incidence of thrombosis remain unclear.
Citation: Thrombosis Journal 2016 14:2
Thus far, validated whole blood assays used in in vitro fibrinolysis experiments using thromboelastometry (ROTEM) are lacking or have yet to be tested in humans.
Citation: Thrombosis Journal 2016 14:1
The aim of the study was to discuss the results of catheter-directed thrombolysis and complementary procedures to treat acute iliofemoral deep vein thrombosis (DVT) evaluating the safety and effectivness of an...
Citation: Thrombosis Journal 2015 13:40
Dabigatran is an alternative to warfarin (WF) for the thromboprophylaxis of stroke in patients with non-valvular atrial fibrillation (NVAF). The advantage of dabigatran over WF is that monitoring is not requir...
Citation: Thrombosis Journal 2015 13:39
Although aspirin has a well-established role in preventing adverse events in patients with known cardiovascular disease (CVD), its benefit in patients without a history of CVD remains under scrutiny. Current d...
Citation: Thrombosis Journal 2015 13:38
The aim of this study was to assess the safety and efficacy of switching therapy from low molecular weight heparin (LMWH; enoxaparin) to dabigatran for prevention of venous thromboembolic events (VTE) in patie...
Citation: Thrombosis Journal 2015 13:37
Two phase 3 trials compared 28–35 days of treatment with oral dabigatran 220 mg or 150 mg (RE-NOVATE) or 220 mg (RE-NOVATE II) once daily with subcutaneous enoxaparin 40 mg once daily for prevention of venous ...
Citation: Thrombosis Journal 2015 13:36
Venous thromboembolism (VTE) could be manifested as deep venous thrombosis (DVT) or pulmonary embolism (PE). DVT is usually the more common manifestation and is usually formation of a thrombus in the deep vein...
Citation: Thrombosis Journal 2015 13:35
Venous thromboembolism (VTE) is a major health problem, with over one million events every year in Europe. However, there is a paucity of data on the current management in real life, including factors influenc...
Citation: Thrombosis Journal 2015 13:41
The aim was to assess the risk of venous thromboembolism (VTE) associated with use of combined oral contraceptives (COCs) in women with a family history of VTE.
Citation: Thrombosis Journal 2015 13:34
Deep vein thrombosis (DVT) and pulmonary emboli (PE), known together as venous thromboembolic (VTE) disease remain major complications following elective hip and knee surgery. This study compares three chemopr...
Citation: Thrombosis Journal 2015 13:32
Venous thromboembolism [VTE] is a common medical condition that has significant morbidity and mortality. Although stringent guidelines recommend lifelong anticoagulation for patients with unprovoked VTE, the o...
Citation: Thrombosis Journal 2015 13:33
Platelet activation, thrombin generation and fibrin formation play important roles in intracoronary thrombus formation, which may lead to acute myocardial infarction.
Citation: Thrombosis Journal 2015 13:31
We report a case of unsuccessful percutaneous mechanical thrombectomy in treatment of a high-risk pulmonary embolism (PE). Pulmonary thromboemboli are commonly expected as a homogenous mass, rich with red bloo...
Citation: Thrombosis Journal 2015 13:30
Dual antiplatelet therapy based on the combination of an adenosine diphosphate (ADP)-receptor antagonist plus aspirin has demonstrated to be more effective in reducing the rate of major ischemic vascular event...
Citation: Thrombosis Journal 2015 13:28
Atrial fibrillation (AF) puts patients at risk of complications, including stroke. Warfarin therapy has been the mainstay of antithrombotic treatment for reducing the risk of stroke in AF. However, warfarin ha...
Citation: Thrombosis Journal 2015 13:29
In the absence of thromboprophylaxis, patients undergoing total hip arthroplasty (THA) are at increased risk for venous thromboembolism (VTE). The objective of this study was to compare the efficacy and safety...
Citation: Thrombosis Journal 2015 13:27
Although quantitative anti-FXa assays can be used to measure rivaroxaban plasma levels, they are not widely performed or available. We aimed to tentatively determine the cut-off for thromboembolism and bleedin...
Citation: Thrombosis Journal 2015 13:26
A 43-year-old woman recipient of a bare metal coronary stent during an acute anterior myocardial infarction was repeatedly hospitalized with recurrent stent thrombosis (ST) over the following 3 years. Emergent...
Citation: Thrombosis Journal 2015 13:25
Plasma phospholipid transfer protein (PLTP) transfers lipids between donors and acceptors (e.g., from HDL to VLDL) and modulates lipoprotein composition, size, and levels. No study has reported an assessment of t...
Citation: Thrombosis Journal 2015 13:24
Warfarin, dabigatran, and apixaban are used for preventing ischemic stroke due to non-valvular atrial fibrillation (NVAF). However, it is often challenging to select the appropriate anticoagulant. We present t...
Citation: Thrombosis Journal 2015 13:23
Thrombosis Journal is the official journal of the Asian-Pacific Society on Thrombosis and Hemostasis.
Members of APSTH are entitled to a 15% discount on the article processing charge.
Speed
51 days to first decision for reviewed manuscripts only
48 days to first decision for all manuscripts
102 days from submission to acceptance
45 days from acceptance to publication
Citation Impact
2.295- Impact Factor
1.235 - Source Normalized Impact per Paper (SNIP)
10.895 - SCImago Journal Rank (SJR)
Usage
270,557 Downloads
242 Altmetric mentions